This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Poniard Predictions

BOSTON ( TheStreet) -- Let's open the Biotech Stock Mailbag, beginning with an email from Leslie O. about a very important event looming for Poniard Pharmaceuticals (PARD).

Writes Leslie, " Adam, what's your prediction for results from Poniard's phase III study of picoplatin in small cell lung cancer?"

I have no edge on this one, so I don't have a prediction for you. Needless to say, this is a huge event for Poniard. A successful study lands the company a partnership and a nice bump in the stock price. I'll guess in the $12-plus range. A negative outcome get reported, and Poniard shares will plummet towards cash levels of around $1. The stock was trading Thursday at around $7.

Poniard has guided to data before the end of November.

Picoplatin is a next-generation platinum chemotherapy drug designed to overcome resistance to prior platinum therapy. The drug may also cause less nerve-related toxicity.

The phase III study, dubbed "SPEAR," compares treatment with picoplatin against best supportive care (BSC) in second-line small cell lung cancer (SCLC) patients. These are patients with advanced, progressive disease after treatment with a front-line platinum agent. The primary endpoint of the study is overall survival.

The bull story: A published single-arm phase II study of picoplatin in SCLC patients demonstrated a median overall survival of 27 weeks. Best supportive care (BSC) in this patient population is believed to yield a median survival of around 14 weeks (again, from prior published studies.)

Poniard designed the SPEAR study conservatively so that picoplatin patients need only reach a 19-week median survival for the study to be a success, based on the assumption of a 14-week median survival for patients treated with BSC. Patients in the BSC arm are also prohibited from being treated with other chemotherapies in the second line, which could, in theory, hurt picoplatin's chances of showing a significant survival benefit.
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CHTP $0.00 0.00%
DNDN $0.06 -6.02%
PARD $0.12 0.00%
AMAG $22.03 0.00%
AMGN $156.35 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs